EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma

Abdula Monther iD, Riyam Al-Msari, Robert Saddawi-Konefka, Santiago Fassardi, Cynthia Tang, Chad Philips, Prakriti Sen, Pardis Mohammadzadeh, Kelsey Decker, Sayuri Miyauchi iD, Souvick Roy iD, Riley Jones iD und 4 weitere

PLOS One · 2026

DOI: 10.1371/journal.pone.0328031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Abdula Monther und 15 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, UC San Diego, La Jolla, California United States of America. Hauptthemen laut MEDLINE: CD47 Antigen, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa interaction that inhibits antigen-presenting cell phagocytosis, thereby enhancing antigen presentation to cytotoxic T-cells, and have shown promise in combination with anti-PD1 immunotherapy in tumors, including recurrent/metastatic HNSCC. We found that CD47 expression is associated with poor prognosis in HNSCC and explored the anti-tumor activity of an anti-CD47 fusion protein in combination with anti-PD1 and lymphatic-sparing radiotherapy in a locally advanced HNSCC model. In the 4MOSC1 syngeneic HPV-negative HNSCC mouse model, ALX301 (an engineered CD47-blocking SIRPα fusion for murine models) induced complete tumor regression when combined with anti–PD-1, and produced a partial tumor response as a monotherapy. An anti-PD1 immune checkpoint inhibitor in a CD47-null tumor background led to complete tumor regression confirming a key role for CD47 in tumor immunity. ALX301 treated mice demonstrated increased MHC-II expression on dendritic cells within the tumor and upregulation of CD86 co-stimulatory molecule on dendritic cells within the tumor, sentinel lymph nodes, and contralateral lymph nodes. Combination ALX301 and anti-PD1 treatment in an anti-PD1 resistant 4MOSC2 model demonstrated significant tumor regression, enhanced survivability, improved response with neoadjuvant radiotherapy, and greater retention of CD8 + T-cells within the tumor microenvironment. Notably, T-cell receptor sequencing revealed increased shared clonality between the tumor and sentinel lymph nodes of ALX301 treated mice. These data demonstrate that a combination of CD47 blockade and anti-PD1 therapy enhances tumor antigen presentation and immune cell infiltration, while further improving anti-tumor responses in combination with tumor-targeted radiotherapy. This study provides support for the rational design of combinatorial immunoradiotherapy, using anti-CD47 inhibitors and anti-PD1 therapy, in a clinical trial targeting locally advanced HPV-negative HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsRecombinant Fusion ProteinsAnimalsMiceHumansCell Line, TumorFemaleImmunotherapyReceptors, Immunologic

Substanzen

CD47 AntigenReceptors, ImmunologicRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Moores Cancer Center, UC San Diego, La Jolla, California United States of America.
  • University of California-San Diego School of Medicine, La Jolla, California, United States of America.
  • Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, California, United States of America.
  • Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, California, United States of America.
  • Department of Pharmacology, UC San Diego, La Jolla, California, United States of America.

ORCID-Profile: Abdula Monther, Sayuri Miyauchi, Souvick Roy, Riley Jones, Joseph Califano

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Monther, A., Al-Msari, R., Saddawi-Konefka, R., Fassardi, S., Tang, C., Philips, C., Sen, P., Mohammadzadeh, P., Decker, K., Miyauchi, S., Roy, S., Jones, R., Wu, X., Gutkind, S., Sharabi, A., & Califano, J. (2026). CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma. PLOS One. https://doi.org/10.1371/journal.pone.0328031

Vancouver

Monther A, Al-Msari R, Saddawi-Konefka R, Fassardi S, Tang C, Philips C, et al. CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma. PLOS One. 2026. doi:10.1371/journal.pone.0328031

BibTeX
@article{Monther2026,
  author = {Monther, Abdula and Al-Msari, Riyam and Saddawi-Konefka, Robert and Fassardi, Santiago and Tang, Cynthia and Philips, Chad and Sen, Prakriti and Mohammadzadeh, Pardis and Decker, Kelsey and Miyauchi, Sayuri and Roy, Souvick and Jones, Riley and Wu, Xingyu and Gutkind, Silvio and Sharabi, Andrew and Califano, Joseph},
  title = {CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0328031}
}
Kostenlos starten →